Drug profile · INN
spesolimab-sbzo
SPEVIGO
spesolimab-sbzo (SPEVIGO) is a il36 receptor antagonist. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — spesolimab-sbzo
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
spesolimab-sbzo (SPEVIGO) is a il36 receptor antagonist. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
IL36 receptor antagonist
Primary target: IL36 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is spesolimab-sbzo?
spesolimab-sbzo (SPEVIGO) is a il36 receptor antagonist. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for spesolimab-sbzo?
SPEVIGO is a marketed brand name for spesolimab-sbzo. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of spesolimab-sbzo?
spesolimab-sbzo has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.